The US Food and Drug Administration (FDA) has granted priority review to United Kingdom-based AstraZeneca's cancer drug Imfinzi (durvalumab) intended for the treatment of extensive-stage small cell lung cancer (SCLC) in earlier untreated patients, it was reported on Friday.
The company has submitted the drug's supplemental Biologics License Application for its approval in extensive SCLC in treatment-naive patients based on the results from the phase three CASPIAN trial. AstraZeneca has said that results from the phase 3 trial showed an estimated 33.9% of patients survived at 18 months after receiving the investigational treatment compared to 24.7% of patients who were on SoC treatment.
The product's Prescription Drug User Fee Act (PUDFA) date for the SCLC indication has been set for the first quarter of 2020 by the US FDA. The oncology immunotherapy was earlier granted orphan drug designation for the same indication by the US FDA in July 2019.
Privo Technologies reports progress in oral cancer trial
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application